Filing Flows › QHSLab (USAQ) › Q1 2026 › vs Q4 2025
QHSLab (USAQ) Q1 2026 vs Q4 2025 (quarter over quarter)
QHSLab's revenue rose $25K (+4%) from $704K in Q4 2025 to $729K in Q1 2026. The biggest changes: Allergy Diagnostic Kit Sales +$85K (+59%); Immunotherapy Treatment Sales −$48K (-35%); Integrated Service Program +$39K (+12%).
QHSLab, Q1 2026: revenue $729K (+13% year over year), operating margin -13.0%, net loss $104K, operating cash flow −$200K. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Integrated Service Program | $375K | $336K | $39K | +12% |
| Allergy Diagnostic Kit Sales | $229K | $144K | $85K | +59% |
| Immunotherapy Treatment Sales | $91K | $139K | −$48K | -35% |
| Subscription Revenue | $12K | $9K | $3K | +28% |
| Shipping and Handling | $12K | $10K | $1K | +15% |
| Training and Other Revenue | $11K | $21K | −$10K | -49% |
| Revenue | $729K | $704K | $25K | +4% |
| Net loss | $104K | −$557K | $660K | — |
| Costs & expenses | $833K | $1.2M | −$392K | -32% |
| Operating costs | $823K | $668K | $155K | +23% |
| Interest & other, net | $10K | −$521K | $531K | — |
| Cost of revenue | $258K | $216K | $42K | +20% |
| Research & development | $121K | $116K | $5K | +4% |
| Sales & marketing | $218K | $198K | $20K | +10% |
| General & admin | $208K | $121K | $87K | +72% |
| Other operating costs | $18K | $18K | $0 | 0% |
| Operating cash sources | $218K | $276K | −$58K | -21% |
| Depreciation & amortization | $18K | $18K | $0 | 0% |
| Cash used in operations | $200K | $258K | −$58K | -22% |
| Net loss absorbed | $104K | −$557K | $660K | — |
| Working capital & other | $114K | $833K | −$718K | -86% |
Questions
How much did QHSLab's revenue grow quarter over quarter in Q1 2026?
QHSLab's revenue rose $25K (+4%) from $704K in Q4 2025 to $729K in Q1 2026.
What drove QHSLab's revenue change in Q1 2026?
Allergy Diagnostic Kit Sales +$85K (+59%); Immunotherapy Treatment Sales −$48K (-35%); Integrated Service Program +$39K (+12%).